Armistice Capital, LLC Reports 7.8% Stake in Revelation Biosciences, Inc. (REVB) after Reducing Position

On May 15, 2026, Armistice Capital, LLC and Steven Boyd filed a Schedule 13G regarding their holdings in Revelation Biosciences, Inc. (REVB). The filing reveals that as of March 31, 2026, the reporting persons beneficially own 323,241 shares of common stock, representing a 7.8% ownership stake in the company. This reflects a decrease from their previously reported position of 434,272 shares. Armistice Capital, LLC serves as the investment manager for the Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to have beneficial ownership. The shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The reporting persons share voting and dispositive power over the disclosed shares. This filing underscores Armistice Capital's continued, though reduced, significant investment in the San Diego-based biopharmaceutical company.